DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

DURECT Corporation (Nasdaq: DRRX) will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, from 1:20 PM - 1:50 PM EDT. Dr. James E. Brown, Dr. WeiQi Lin, and Dr. Norman Sussman will discuss the company’s progress in clinical development, focusing on their lead candidate, Larsucosterol (DUR-928), which targets alcohol-associated hepatitis and has received FDA Fast Track Designation. Additionally, the company’s non-opioid analgesic POSIMIR is licensed to Innocoll Pharmaceuticals for development in the U.S.

Positive

• Larsucosterol (DUR-928) targeting alcohol-associated hepatitis has FDA Fast Track Designation.
• POSIMIR, a non-opioid analgesic, is FDA-approved and licensed for U.S. development.

Negative

• Potential risks and uncertainties include delays in clinical trials due to COVID-19.
• Risk that ongoing trials may not confirm earlier positive results or demonstrate significant safety and efficacy.

CUPERTINO, Calif., March 9, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr. Norman Sussman, Chief Medical Officer, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 32^nd Annual Healthcare Conference on Tuesday, March 15, 2022.

Presentation details are as follows:

Oppenheimer 32nd Annual Healthcare Conference
Date:	March 15, 2022
Time:	1:20pm – 1:50pm Eastern Daylight Time
Format:	Fireside chat hosted by Francois Brisebois
Webcast:	https://wsw.com/webcast/oppenheimer20/drrx/2810304

The webcast link of the presentation will also be available by accessing DURECT's homepage at www.durect.com and clicking on "Event Calendar" under the "Investors" section.

About DURECT Corporation

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. Larsucosterol (also known as DUR-928), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for development and commercialization in the United States. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.

DURECT Forward-Looking Statement

The statements in this press release regarding clinical development of larsucosterol (DUR-928) for potential treatment of AH, the potential to develop larsucosterol for NASH or other indications, the expected commercial launch of POSIMIR by Innocoll and potential future payments we may receive from Innocoll are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the AHFIRM trial of larsucosterol in AH takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that ongoing and future clinical trials of larsucosterol do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the life-saving potential of larsucosterol in a statistically significant manner,  risks that Innocoll may not commercialize POSIMIR successfully, if at all, and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's annual report on Form 10-K filed on March 8, 2022 with the Securities and Exchange Commission under the heading "Risk Factors."  The 10-K and other public filings are available on our website www.durect.com under the "Investors" tab.

NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER® is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. Larsucosterol (DUR-928) is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.

View original content:https://www.prnewswire.com/news-releases/durect-corporation-fireside-chat-at-the-oppenheimer-32nd-annual-healthcare-conference-301499423.html

SOURCE DURECT Corporation

FAQ

What is DURECT Corporation's upcoming event?

DURECT Corporation will participate in the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022.

What will be discussed at the Oppenheimer Conference for DURECT?

DURECT's leadership will discuss the clinical development of their lead drug candidate, Larsucosterol, and its FDA Fast Track Designation.

What is Larsucosterol, and what is it being developed for?

Larsucosterol (DUR-928) is being developed for the treatment of alcohol-associated hepatitis.

What is the status of POSIMIR from DURECT Corporation?

POSIMIR is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for commercialization in the U.S.

What are the risks mentioned in DURECT's press release?

Risks include potential delays in clinical trials and the possibility that ongoing trials may not confirm earlier results.